Pfizer Inc. (NYSE:PFE) Stake Boosted by C M Bidwell & Associates Ltd.

C M Bidwell & Associates Ltd. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 27.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,620 shares of the biopharmaceutical company’s stock after buying an additional 2,900 shares during the quarter. C M Bidwell & Associates Ltd.’s holdings in Pfizer were worth $361,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PSI Advisors LLC raised its position in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. boosted its holdings in shares of Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton grew its position in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC increased its stake in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 401 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.8 %

Shares of NYSE:PFE opened at $25.20 on Monday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $142.93 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The stock’s 50-day moving average is $26.06 and its 200-day moving average is $26.90.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the business posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PFE. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.